by in Biopharma, Multiplex Immunohistochemistry

Myelodysplastic Syndromes Global Support

For myelodysplastic syndromes, current therapy is selected based on risk, transfusion needs, percent of bone marrow blasts, cytogenetic and mutational profiles, comorbidities, potential for allogeneic stem cell transplantation (alloSCT), and prior exposure to hypomethylating agents (HMA). Better diagnosis and prognostic stratification may allow a more precise and personalized treatment of MDS with novel agent combinations, […]